OTCMKTS:ELTP Elite Pharmaceuticals (ELTP) Stock Price, News & Analysis → Millionaire-Making “Wealth Pattern” Just Repeated on April 22 (From Paradigm Press) (Ad) Free ELTP Stock Alerts $0.17 0.00 (0.00%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$0.16▼$0.1750-Day Range$0.12▼$0.1852-Week Range$0.03▼$0.21Volume459,600 shsAverage Volume565,875 shsMarket Capitalization$179.63 millionP/E Ratio16.83Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Elite Pharmaceuticals alerts: Email Address Ad Augury ResearchBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is currently auctioning off CITGO (the winning bid will be announced on July 22nd).Get all the details here. About Elite Pharmaceuticals Stock (OTCMKTS:ELTP)Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.Read More ELTP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELTP Stock News HeadlinesMay 20, 2024 | finanznachrichten.deElite Pharmaceuticals, Inc.: Elite Pharmaceuticals Receives FDA Approval for Generic MethotrexateApril 26, 2024 | msn.comElite global firm McKinsey in US Justice Department hot chair over Opioid crisisApril 17, 2024 | finance.yahoo.comElite Pharmaceuticals, Inc. (ELTP)February 16, 2024 | finance.yahoo.comElite Pharmaceuticals, Inc. (PNK:ELTP) Q3 2024 Earnings Call TranscriptFebruary 14, 2024 | finance.yahoo.comElite Pharmaceuticals Inc Reports Significant Revenue and Operating Profit Growth in Q3 Fiscal 2024February 14, 2024 | finance.yahoo.comElite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call InformationFebruary 8, 2024 | finance.yahoo.comElite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024January 15, 2024 | thestreet.comElite Pharmaceuticals, Inc.December 26, 2023 | finance.yahoo.comElite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System StimulantDecember 12, 2023 | msn.comElite Pharmaceuticals makes first product shipment of generic Adderall XR to PrascoDecember 12, 2023 | finance.yahoo.comElite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLCNovember 24, 2023 | morningstar.comElite Pharmaceuticals Inc ELTPNovember 20, 2023 | finance.yahoo.comElite Pharmaceuticals, Inc. (PNK:ELTP) Q2 2024 Earnings Call TranscriptNovember 14, 2023 | msn.comElite Pharmaceuticals reports Q3 resultsNovember 14, 2023 | finance.yahoo.comElite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call InformationNovember 10, 2023 | finance.yahoo.comElite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023September 25, 2023 | finance.yahoo.comElite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic ProductSeptember 7, 2023 | msn.comElite Pharmaceuticals reappoints Carter Ward as CFOSeptember 7, 2023 | finance.yahoo.comElite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial OfficerAugust 28, 2023 | finanznachrichten.deElite Pharmaceuticals, Inc.: Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence StudyAugust 28, 2023 | benzinga.comThis Week's Top OTC Nano-Caps (ATVK, ELTP, EBET, ENZC)August 22, 2023 | benzinga.comDiscover the Potential: "Top Penny Stocks to Watch Now": SNNC, TIVC, ENZC, ELTP, CLNVAugust 14, 2023 | seekingalpha.comElite Pharmaceuticals reports Q1 resultsAugust 14, 2023 | finance.yahoo.comElite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call InformationAugust 9, 2023 | finance.yahoo.comElite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023See More Headlines Receive ELTP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elite Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/14/2018Today6/08/2024Next Earnings (Estimated)6/29/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ELTP CUSIPN/A CIK1053369 Webwww.elitepharma.com Phone(201) 750-2646Fax201-750-2755Employees53Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.01 Trailing P/E Ratio16.83 Forward P/E RatioN/A P/E GrowthN/ANet Income$3.56 million Net Margins32.87% Pretax Margin-5.04% Return on Equity41.32% Return on Assets26.72% Debt Debt-to-Equity Ratio0.08 Current Ratio1.94 Quick Ratio1.19 Sales & Book Value Annual Sales$34.15 million Price / Sales5.26 Cash Flow$0.00 per share Price / Cash Flow35.08 Book Value$0.03 per share Price / Book5.61Miscellaneous Outstanding Shares1,068,270,000Free Float914,228,000Market Cap$179.63 million OptionableNot Optionable Beta-0.08 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Nasrat Hakim (Age 63)Chairman, CEO & President Comp: $1.08MMr. Douglas Plassche (Age 60)Executive Vice President of Operations Comp: $540.56kMr. Kirko KirkovChief Commercial OfficerMr. Carter J. Ward CPA (Age 60)CSCP, Chief Financial Officer Comp: $226.2kMs. Dianne WillVice President of Investor Relations & Corporate AffairsDr. George Kenneth Smith J.D.M.B.A., Ph.D., Vice President of LegalMore ExecutivesKey CompetitorsLongboard PharmaceuticalsNASDAQ:LBPHPhibro Animal HealthNASDAQ:PAHCNuvation BioNYSE:NUVBOlema PharmaceuticalsNASDAQ:OLMAAnaptysBioNASDAQ:ANABView All Competitors ELTP Stock Analysis - Frequently Asked Questions How have ELTP shares performed in 2024? Elite Pharmaceuticals' stock was trading at $0.14 at the start of the year. Since then, ELTP shares have increased by 20.1% and is now trading at $0.1682. View the best growth stocks for 2024 here. When is Elite Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Saturday, June 29th 2024. View our ELTP earnings forecast. How were Elite Pharmaceuticals' earnings last quarter? Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP) announced its quarterly earnings results on Thursday, June, 14th. The specialty pharmaceutical company reported $0.00 earnings per share for the quarter. The specialty pharmaceutical company had revenue of $1.60 million for the quarter. Elite Pharmaceuticals had a trailing twelve-month return on equity of 41.32% and a net margin of 32.87%. What other stocks do shareholders of Elite Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Elite Pharmaceuticals investors own include Research Frontiers (REFR), Co-Diagnostics (CODX), Novavax (NVAX), iBio (IBIO), Ascent Solar Technologies (ASTI), Inovio Pharmaceuticals (INO), Selecta Biosciences (SELB), SANUWAVE Health (SNWV) and Sierra Oncology (SRRA). How do I buy shares of Elite Pharmaceuticals? Shares of ELTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ELTP) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elite Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elite Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.